AstraZeneca PLC Company Leadership
AZN Stock | USD 64.26 1.06 1.68% |
AstraZeneca PLC employs about 89.9 K people. The company is managed by 31 executives with a total tenure of roughly 216 years, averaging almost 6.0 years of service per executive, having 2900.0 employees per reported executive. Analysis of AstraZeneca PLC's management performance can provide insight into the firm performance.
Pascal Soriot CEO CEO, Executive Director and Member of Disclosure Committee |
Leif Johansson Chairman Non-Executive Independent Chairman of the Board |
AstraZeneca |
AstraZeneca PLC's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AstraZeneca PLC's future performance. Based on our forecasts, it is anticipated that AstraZeneca will maintain a workforce of about 89900 employees by December 2024.AstraZeneca PLC's latest congressional trading
Congressional trading in companies like AstraZeneca PLC ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AstraZeneca PLC by those in governmental positions are based on the same information available to the general public.
2021-12-14 | Representative Alan S Lowenthal | Acquired Under $15K | Verify | ||
2021-08-13 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
2021-03-05 | Representative Alan S Lowenthal | Acquired $1,001 - | Verify | ||
2020-12-23 | Representative Greg Gianforte | Acquired Under $15K | Verify |
AstraZeneca PLC Management Team Effectiveness
The company has Return on Asset of 0.085 % which means that on every $100 spent on assets, it made $0.085 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1666 %, implying that it generated $0.1666 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Return On Assets are very stable compared to the past year. As of the 22nd of November 2024, Asset Turnover is likely to grow to 0.79, while Total Current Assets are likely to drop about 15.3 B.As of the 22nd of November 2024, Net Income Applicable To Common Shares is likely to grow to about 3.2 B, while Common Stock Shares Outstanding is likely to drop about 2.9 B.
AstraZeneca PLC Workforce Comparison
AstraZeneca PLC ADR is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 259,599. AstraZeneca PLC totals roughly 89,900 in number of employees claiming about 35% of equities under Health Care industry.
AstraZeneca PLC Profit Margins
The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.2 %, which entails that for every 100 dollars of revenue, it generated $0.2 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.87 | 0.8195 |
|
| |||||
Net Profit Margin | 0.1 | 0.13 |
|
| |||||
Operating Profit Margin | 0.22 | 0.1788 |
|
| |||||
Return On Assets | 0.1 | 0.0589 |
|
| |||||
Return On Equity | 0.14 | 0.1521 |
|
|
AstraZeneca PLC ADR Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. AstraZeneca PLC ADR Price Series Summation is a cross summation of AstraZeneca PLC price series and its benchmark/peer.
AstraZeneca PLC Notable Stakeholders
An AstraZeneca PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AstraZeneca PLC often face trade-offs trying to please all of them. AstraZeneca PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AstraZeneca PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal Soriot | CEO, Executive Director and Member of Disclosure Committee | Profile | |
Leif Johansson | Non-Executive Independent Chairman of the Board | Profile | |
Jose Baselga | Executive Vice President - Research & Development Oncology | Profile | |
Katarina Ageborg | Executive Vice President - Sustainability, Chief Compliance Officer | Profile | |
Fiona Cicconi | Executive Vice President - Human Resources | Profile | |
Leon Wang | Executive Vice President - International and China President | Profile | |
Pam Cheng | Executive Vice-President of Operations and Information Technology | Profile | |
Ruud Dobber | Executive Vice President, BioPharmaceuticals Business | Profile | |
David Fredrickson | Executive Vice-President Global Head Oncology Business Unit | Profile | |
Menelas Pangalos | Executive Vice President - Research & Development BioPharmaceuticals | Profile | |
Iskra Reic | Executive Vice President - Europe and Canada | Profile | |
Marc Dunoyer | Chief Financial Officer, Executive Director | Profile | |
Sherilyn McCoy | Non-Executive Independent Director | Profile | |
Genevieve Berger | Non-Executive Independent Director | Profile | |
Nazneen Rahman | Non-Executive Independent Director | Profile | |
Tony Mok | Non-Executive Independent Director | Profile | |
Deborah DiSanzo | Non-Executive Independent Director | Profile | |
Michel Demare | Non-Executive Independent Director | Profile | |
Graham Chipchase | Senior Non-Executive Independent Director | Profile | |
Philip Broadley | Non-Executive Independent Director | Profile | |
Marcus Wallenberg | Non-Executive Director | Profile | |
Deborah Eldracher | Non-Executive Independent Director | Profile | |
Chris Sheldon | Head Relations | Profile | |
Adrian Kemp | Company Secretary | Profile | |
Susan MD | Executive Development | Profile | |
MBA DVM | CEO Director | Profile | |
Aradhana MD | CFO Director | Profile | |
Jeffrey Pott | General Counsel | Profile | |
Jeffrey JD | Chief CHRO | Profile | |
Gonzalo Vina | Head Relations | Profile | |
Andrew Barnett | Head Relations | Profile |
About AstraZeneca PLC Management Performance
The success or failure of an entity such as AstraZeneca PLC ADR often depends on how effective the management is. AstraZeneca PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AstraZeneca management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AstraZeneca management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.14 | 0.11 | |
Return On Capital Employed | 0.12 | 0.11 | |
Return On Assets | 0.06 | 0.10 | |
Return On Equity | 0.15 | 0.14 |
AstraZeneca PLC Workforce Analysis
Traditionally, organizations such as AstraZeneca PLC use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AstraZeneca PLC within its industry.AstraZeneca PLC Manpower Efficiency
Return on AstraZeneca PLC Manpower
Revenue Per Employee | 509.6K | |
Revenue Per Executive | 1.5B | |
Net Income Per Employee | 76.7K | |
Net Income Per Executive | 222.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.07 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.